Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DC AML Vaccine · 1 trial · 2 indications
Participants were assessed for adverse events associated with treating AML patients with DC/AML fusion cells in the post-chemotherapy setting. Adverse event monitoring occurred monthly through 6 months following the last vaccine (up to 9 months) or until time of disease progression (whichever occurred first.)
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | DC AML Fusion Vaccine |
| Name | Type | Description |
|---|---|---|
| DC AML Vaccine | BIOLOGICAL | Group 1: 2-3 doses of the vaccine at 4 week intervals |
Inclusion Criteria: Screening: * Patients with AML at initial diagnosis or at first relapse * 18 years of age or older * ECOG Performance Status 0-2 * Life expectancy of greater than 9 weeks * Laboratory values within limits outlined in the protocol * Women of child-bearing potential and men must ...
DC AML Vaccine is an investigational therapy being studied for Acute Myelogenous Leukemia (AML). It is a dendritic cell vaccine designed to be given following chemotherapy-induced remission. The vaccine is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
DC AML Vaccine is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this investigational therapy for Acute Myelogenous Leukemia.
DC AML Vaccine is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA or other regulatory agencies. The Phase 2 trial has been completed, and the therapy remains under investigation for Acute Myelogenous Leukemia.
DC AML Vaccine has been studied in one completed Phase 2 clinical trial, NCT01096602, titled 'Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission.' The trial enrolled 63 participants in the United States and included adults aged 18 years and older.
DC AML Vaccine is classified as a monoclonal antibody modality, though it is described as a dendritic cell vaccine. It is being investigated for use in Acute Myelogenous Leukemia following chemotherapy-induced remission. The therapy is in Phase 2 clinical development.